Advice
following an abbreviated submission:
levofloxacin plus dexamethasone (Ducressa®) is accepted for use within NHSScotland.
Indication under review: for prevention and treatment of inflammation, and prevention of infection associated with cataract surgery in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
There is no significant additional cost associated with the combination product compared with the individual components and it allows patients to administer fewer drops.
Download detailed advice722KB (PDF)
Medicine details
- Medicine name:
- levofloxacin plus dexamethasone (Ducressa)
- SMC ID:
- SMC2511
- Indication:
Prevention and treatment of inflammation, and prevention of infection associated with cataract surgery in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- Pharmaceutical company
- Santen
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 November 2022